Pulmozyme Financial Support Center: Overview for Patients and Legally Authorized Persons

About Financial Support Center

Pulmozyme Financial Support Center provides you with information and guidance on financial assistance options for Pulmozyme. You can use this site to learn more about our programs, find out if you are eligible, and enroll. Plus, your eligibility and enrollment information will be stored in your account for quick and easy access.

How Financial Support Center works

To check your eligibility and enroll in a program, you need to register with us by filling out a form and creating a password. From there, you will be directed to the appropriate assistance option for you.

Program description

The Pulmozyme Co-pay Program works to help eligible, commercially insured patients pay as little as $30 for a 30-day supply of Pulmozyme. The Pulmozyme Co-pay Program covers any additional out-of-pocket costs for Pulmozyme, after you pay $30 for each 30-day supply, up to $10,000 per calendar year, for most privately insured patients.

Program eligibility requirements

Patients may be eligible for the Co-pay Program if they:

Have been prescribed Pulmozyme for an FDA-approved indication
Are 18 years of age or older, or have a caregiver or have a legally authorized person to manage the patient's co-pay assistance
Have commercial (private or non-governmental) insurance.* This includes plans available through state and federal health insurance exchanges
Reside and receive treatment in the United States or U.S. Territories
Are not receiving assistance through the Genentech Patient Foundation or any other charitable organization for the same expenses covered by the program
Are not a government beneficiary and/or participant in a federal or state-funded health insurance program (e.g., Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE)

*Commercial insurance includes plans you receive from your job or plans from the Health Insurance Marketplace. Government programs like Medicare and Medicaid are not commercial insurance.

If a patient is not eligible for the Pulmozyme Co-pay Program, there may be other options for co-pay assistance. Call (866) 422-2377 or visit genentech-access.com/pulmozyme.html to learn more.

Please see Terms and Conditions for full eligibility requirements.

How to enroll with Financial Support Center

Once you have registered with us, you will be directed to the savings program that is right for you.

Once you have enrolled in the Co-pay Program, your card information will be stored on this site under your account. You can log in at any time to view your account balance, print your card, or request that a copy be emailed to you.

The importance of creating an account

We request that you provide some personal information and create an account so that we can recognize you whenever you visit the site and provide you with the most personalized support possible. With unique login information, you will be able to access your card information or easily activate a new card, so you don't have to worry if it gets lost or expires.

GET STARTED

Important Safety Information & Indication

Indication and Usage

Pulmozyme (dornase alfa) is indicated, along with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme along with standard therapies for cystic fibrosis have been established in pediatric patients. The use of Pulmozyme in pediatric patients at 5 to 17 years of age is supported by evidence from a randomized, controlled trial. The use of Pulmozyme in patients less than 5 years of age is supported by the efficacy data from the same randomized, controlled trial and additional safety data in pediatric patients aged 3 months to less than 5 years who received Pulmozyme.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

For further information, please see the full Pulmozyme Prescribing Information. If you have questions, please discuss them with your CF Care Team.